Leerink Partnrs Has Optimistic Outlook of SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at Leerink Partnrs boosted their Q1 2025 earnings per share estimates for shares of Solid Biosciences in a research note issued to investors on Sunday, February 23rd. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.36) for the quarter, up from their prior forecast of ($0.81). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.46) EPS and FY2026 earnings at ($1.54) EPS.

Other equities research analysts have also issued research reports about the stock. Wedbush began coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price objective for the company. JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Chardan Capital boosted their price objective on Solid Biosciences from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Citizens Jmp upgraded Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, JPMorgan Chase & Co. reduced their price target on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Nine analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $15.40.

Solid Biosciences Stock Performance

NASDAQ SLDB opened at $5.29 on Wednesday. The firm has a market capitalization of $214.66 million, a price-to-earnings ratio of -1.74 and a beta of 2.01. Solid Biosciences has a one year low of $2.88 and a one year high of $15.05. The company’s 50 day moving average price is $3.86 and its 200 day moving average price is $5.71.

Insider Activity

In related news, CEO Alexander Cumbo sold 11,114 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the sale, the chief executive officer now directly owns 38,484 shares of the company’s stock, valued at $215,510.40. This represents a 22.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jessie Hanrahan sold 4,610 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $25,816.00. Following the transaction, the insider now directly owns 14,235 shares of the company’s stock, valued at approximately $79,716. This represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 26,069 shares of company stock worth $137,301. 13.63% of the stock is currently owned by insiders.

Institutional Trading of Solid Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of SLDB. Quantum Private Wealth LLC bought a new stake in shares of Solid Biosciences in the 3rd quarter valued at approximately $220,000. Los Angeles Capital Management LLC bought a new stake in Solid Biosciences during the third quarter valued at $293,000. Valence8 US LP acquired a new stake in shares of Solid Biosciences during the third quarter worth $110,000. The Manufacturers Life Insurance Company bought a new position in shares of Solid Biosciences in the 3rd quarter worth about $71,000. Finally, FMR LLC acquired a new position in shares of Solid Biosciences in the 3rd quarter valued at about $305,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.